Skip to main content

Advertisement

SpringerLink
Log in

A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

A pharmacologic analysis of intracavitary doxorubicin in the treatment of patients with intracavitary cancer dissemination was performed to further evaluate the possible benefits of this treatment modality.

Methods

Twenty appendiceal malignancy patients with peritoneal carcinomatosis (PC), three appendiceal malignancy patients with direct extension into the pleural cavity, 20 patients with peritoneal mesothelioma and one patient with pleural mesothelioma were available for pharmacologic monitoring. After intraperitoneal or intrapleural administration of doxorubicin, plasma and peritoneal fluid samples were obtained at 15, 30, 45, 60 and 90 min in all patients. After intrapleural administration, plasma and pleural fluid samples were collected at similar intervals. Tumor and normal tissues were obtained when available. Doxorubicin concentrations were determined by high-performance liquid chromatography (HPLC).

Results

Intraperitoneal doxorubicin showed a prolonged retention in the peritoneal cavity. Doxorubicin concentrations in tumor tissue were consistently elevated above intraperitoneal concentrations from 30 through 90 min. For appendiceal malignancy, the concentrations of doxorubicin were significantly higher in minimally aggressive mucinous tumors. Pleural chemotherapy solutions retained doxorubicin to a greater extent than peritoneal fluid.

Conclusions

Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zoetmulder FA (1982) Modelstudies over het colorectale carcinoom. Amsterdam, Rodopi

    Google Scholar 

  2. Sugarbaker PH, Cunliffe WJ, Belliveau J et al (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16(4):83–97

    PubMed  CAS  Google Scholar 

  3. Weiss L (1990) Metastatic inefficiency. Adv Cancer Res 54:159–211

    Article  PubMed  CAS  Google Scholar 

  4. Sugarbaker PH (2003) Peritonectomy procedures. Surg Oncol Clin N Am 12(3):703–727

    Article  PubMed  Google Scholar 

  5. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(6):1950–1955

    Article  PubMed  CAS  Google Scholar 

  6. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Oncology Group. J Clin Oncol 19(4):1001–1007

    PubMed  CAS  Google Scholar 

  7. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43

    Article  PubMed  CAS  Google Scholar 

  8. Verwaal VJ, Van Ruth S, De Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743

    Article  PubMed  Google Scholar 

  9. Sugarbaker PH (2005) An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 92(2):142–146

    Article  PubMed  Google Scholar 

  10. Cummings J, Stuart JFB, Calman KC (1984) Determination of adriamycin, adriamycinol and their 7-deoxyaclycones in human serum by high-performance liquid chromatography. J Chromatogr 311:125–133

    Article  PubMed  CAS  Google Scholar 

  11. Ronnett BM, Zahn CM, Kurman RJ et al (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19(12):1390–1408

    Article  PubMed  CAS  Google Scholar 

  12. Cerruto CA, Brun EA, Chang D, Sugarbaker PH (2006) Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 130(11):1654–1661

    PubMed  Google Scholar 

  13. Tritton TR (1991) Cell surface actions of adriamycin. Pharmacol Ther 49:293–309

    Article  PubMed  CAS  Google Scholar 

  14. Hahn GM, Braun J, Har-Kedar I (1975) Thermochemotherapy: synergism between hyperthermia (42–43°) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc Nat Acad Sci 72(3):937–940

    Article  PubMed  CAS  Google Scholar 

  15. Lane P, Vichi P, Bain DL et al (1987) Temperature dependence studies of adriamycin uptake and cytotoxocity. Cancer Res 42:4038–4042

    Google Scholar 

  16. Carter SK (1981) Adriamycin—a review. J Natl Cancer Inst 55:1265–1274

    Google Scholar 

  17. Johansen PB (1981) Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 5:267–270

    Article  PubMed  CAS  Google Scholar 

  18. Ozols RF, Young RC, Speyer JL et al (1982) Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–4269

    PubMed  CAS  Google Scholar 

  19. Ozols RF, Grotzinger KR, Fisher RI et al (1979) Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39:3202–3208

    PubMed  CAS  Google Scholar 

  20. Ozols RF, Locker GY, Doroshow JH et al (1979) Pharmacokinetics and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214

    PubMed  CAS  Google Scholar 

  21. Ozols RF, Willson JKV, Weltz MD et al (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109–4112

    PubMed  CAS  Google Scholar 

  22. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10(2):112–122

    Article  PubMed  CAS  Google Scholar 

  23. Roboz J, Jacobs AJ, Holland JF et al (1981) Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 9:245–250

    Article  PubMed  CAS  Google Scholar 

  24. Yan TD, Welch L, Black D et al (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834

    Article  PubMed  CAS  Google Scholar 

  25. Raspagliesi F, Kusamura S, Campos Torres JC et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32(6):671–675

    Article  PubMed  CAS  Google Scholar 

  26. Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14(2):484–492

    Article  PubMed  Google Scholar 

  27. Stelin G, Rippe B (1990) A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 38(3):465–472

    Article  PubMed  CAS  Google Scholar 

  28. Ceelen WP, Påhlman L, Mahteme H (2006) Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. In Peritoneal carcinomatosis: a multidisciplinary approach. Cancer Treat Res, Springer, 195–214

  29. Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89(7):480–487

    Article  PubMed  CAS  Google Scholar 

  30. Sugarbaker PH, Stuart OA (2007) Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. Cancer Chemother Pharmacol 59(2):151–155

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium

    Kurt Van der Speeten

  2. Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA

    O. A. Stuart & P. H. Sugarbaker

  3. Department of Surgical Sciences, Section of Surgery, Akademiska Sjukhuset, Uppsala University Hospital, Uppsala, Sweden

    H. Mahteme

Authors
  1. Kurt Van der Speeten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. A. Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Mahteme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. H. Sugarbaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kurt Van der Speeten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van der Speeten, K., Stuart, O.A., Mahteme, H. et al. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 63, 799–805 (2009). https://doi.org/10.1007/s00280-008-0800-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0800-0

Keywords

Search

Navigation